Immupharma PLC IMM live on Investor Meet Company platform 7 April
April 06 2020 - 2:00AM
RNS Non-Regulatory
TIDMIMM
Immupharma PLC
06 April 2020
6 April 2020
ImmuPharma PLC
("ImmuPharma" or the "Company")
ImmuPharma to present live on 'Investor Meet Company'
platform
Tuesday 7 April 2020 | 10.30am (BST)
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM), a
specialist drug discovery and development company, is pleased to
announce that Tim McCarthy, Chairman of ImmuPharma, will provide a
live presentation relating to the recently announced (30/3/20)
GBP1.5 million Subscription and update on the Company's R&D
programmes, via the 'Investor Meet Company' platform. The live
presentation will be held on Tuesday 7 April 2020 @ 10.30am
(BST).
ImmuPharma is committed to ensuring ongoing communication and
transparency for all elements of its shareholder base, so that its
strategy and progress within its therapy programmes are clearly
communicated and understood. To this end and in order to access and
engage with existing and potential shareholders efficiently,
ImmuPharma has adopted the Investor Meet Company communications
platform.
Questions can be submitted pre-event at investors@immupharma.com
or in real time during the presentation, via the "Ask a Question"
function. ImmuPharma will address all submitted questions within
the confines of information already disclosed to the market through
regulatory notifications. Responses to the Q&A from the live
presentation will be published at the earliest opportunity on the
Investor Meet Company platform.
Investor feedback can also be submitted directly to management
post the event to ensure the Company can understand the views of
all elements of its shareholder base.
Investor Meet Company is a digital platform that provides
individual investors the same direct access to management as
Institutional Investors around company announcements. Through live,
interactive presentations, as part of the investor roadshow, all
investors can now have the same opportunity for two-way engagement
regardless of the number of shares they own or where they are
located so they can come to an informed decision about
ImmuPharma.
Investors interested in hearing more about ImmuPharma can sign
up for free to Investor Meet Company at:
https://www.investormeetcompany.com/register and add to meet
ImmuPharma PLC where they will then be alerted to the forthcoming
live presentation.
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 8974
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Jean-Louis Dubrule +32 (0) 497 50 84 03
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio consists of
four novel peptide therapy areas which are: Autoimmunity,
Metabolism, Cancer and Anti-Infectives. The lead program,
Lupuzor(TM), is a first-in class autophagy immunomodulator which is
in Phase III for the treatment of lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases
that share the same autophagy mechanism of action. ImmuPharma and
Avion Pharmaceuticals signed on 29 November 2019, an exclusive
licence and development agreement and trademark agreement for
Lupuzor(TM) to fund a new international Phase III trial for
Lupuzor(TM) and commercialise in the US. For additional information
about ImmuPharma please visit www.immupharma.com. ImmuPharma's LEI
(Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFLFFVSAIVIII
(END) Dow Jones Newswires
April 06, 2020 02:00 ET (06:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Aug 2023 to Aug 2024